FINWIRES · TerminalLIVE
FINWIRES

Raymond James Downgrades BridgeBio Pharma to Market Perform From Outperform

By

BridgeBio Pharma (BBIO) has an average rating of buy and mean price target of $105.26, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Related Articles

Research

HSBC Downgrades Cosan to Reduce From Hold, Adjusts Price Target to $3.20 From $5

Cosan (CSAN) has an average rating of hold and mean price target of $5.30, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$CSAN
Research

Raymond James Upgrades Tectonic Therapeutic to Strong Buy From Outperform, Adjusts PT to $81 From $76

Tectonic Therapeutic (TECX) has an average rating of buy and mean price target of $78.44, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$TECX
Research

Arete Upgrades Okta to Buy From Sell, Adjusts Price Target to $127 From $83

Okta (OKTA) has an average rating of overweight and mean price target of $100.72, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$OKTA